Stock Groups

Clover’s vaccine 67% effective against COVID, 79% against Delta variant in large trial By Reuters


BEIJING (Reuters) -A potential COVID-19 vaccine from China’s Clover Biopharmaceuticals was 67% effective against COVID-19 of any degree of severity and 79% against the highly infectious Delta variant in a large trial, the company said on Wednesday.

Through the COVAX global vaccine sharing program, Clover Biopharmaceuticals has an agreement to provide up to 414 millions doses of their COVID-19 vaccine.

The company stated that it will submit data from the trials for conditional approval by the World Health Organization as well as regulators in China, Europe and China in the fourth quarter 2021.

At least two weeks following the last dose of large-scale COVID-19, 207 cases with symptoms were reported.

Clover representatives said that 52 of the cases were from the vaccinated population and the rest were placebo-treated.

Gene sequencing was performed on 146 patients. The three most popular variants of the virus were Delta, Gamma or Mu. 73% of these cases had been identified. It analyzed 56 Delta cases as well as 37 Mu and 13 Gamma cases.

Clover CEO Joshua Liang released a statement saying that SCB-1999 had successfully shown efficacy against the Delta-dominant strain as well as other worrying variants.

It was able to protect against mild-to-severe diseases and it protected 100% from hospitalisation and serious cases of COVID-19.

The vaccine also proved to be effective in preventing moderate-to-severe Delta-related cases. Gamma-triggered diseases were 91.8% and Mu was 58.6% respectively.

There were less older vaccine trial participants because they are more likely to experience severe illnesses and death in the real world than those who are younger. Clover explained that enrollment of the older trial participants was restricted because countries in which Clover carried out the trial had begun to immunize the elderly.

Clover provided a slidehow showing that people 65 years and older accounted for less then 1.5% of the vaccinated as well as placebo group. However, all five COVID patients in this age bracket did not get the vaccine.

Dynavax (NASDAQ) has conducted trials that involved more than 3000 participants across the Philippines and South Africa.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. Instead, they are determined by marketmakers. As such, the prices might not reflect market conditions and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.